Literature DB >> 22617226

Effects of CYP induction by rifampicin on tamoxifen exposure.

L Binkhorst1, T van Gelder, W J Loos, F E de Jongh, P Hamberg, I M Ghobadi Moghaddam-Helmantel, E de Jonge, A Jager, C Seynaeve, R H N van Schaik, J Verweij, R H J Mathijssen.   

Abstract

Tamoxifen undergoes biotransformation into several metabolites, including endoxifen. Differences in metabolism contribute to the interindividual variability in endoxifen concentrations, potentially affecting treatment efficacy. We evaluated the effects of cytochrome P450 (CYP) induction by rifampicin on the exposure levels of tamoxifen and its metabolites and found that coadministration of rifampicin resulted in markedly reduced (up to 86%, P ≤ 0.040) concentrations of tamoxifen and its metabolites. Given the extensive metabolism undergone by tamoxifen, several factors may have contributed to this effect. Similar drug-drug interactions may exist between tamoxifen and other strong CYP inducers.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22617226     DOI： 10.1038/clpt.2011.372

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  10 in total

1.  Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Authors:  Lena Klopp-Schulze; Markus Joerger; Sebastian G Wicha; Rob Ter Heine; Chantal Csajka; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

2.  Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.

Authors:  Lisette Binkhorst; Jacqueline S L Kloth; Annelieke S de Wit; Peter de Bruijn; Mei H Lam; Ines Chaves; Herman Burger; Robbert J van Alphen; Paul Hamberg; Ron H N van Schaik; Agnes Jager; Birgit C P Koch; Erik A C Wiemer; Teun van Gelder; Gijsbertus T J van der Horst; Ron H J Mathijssen
Journal:  Breast Cancer Res Treat       Date:  2015-06-07       Impact factor: 4.872

3.  Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.

Authors:  Sara L Henderson; Wendy A Teft; Richard B Kim
Journal:  BMC Cancer       Date:  2016-05-11       Impact factor: 4.430

Review 4.  Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

Authors:  Theodore J Wigle; Laura E Jansen; Wendy A Teft; Richard B Kim
Journal:  J Pers Med       Date:  2017-12-13

5.  The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.

Authors:  Koen G A M Hussaarts; Florine A Berger; Lisette Binkhorst; Esther Oomen-de Hoop; Roelof W F van Leeuwen; Robbert J van Alphen; Daniëlle Mathijssen-van Stein; Natasja M S de Groot; Ron H J Mathijssen; Teun van Gelder
Journal:  Pharm Res       Date:  2019-12-16       Impact factor: 4.200

6.  Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.

Authors:  Barbara Pistilli; Angelo Paci; Arlindo R Ferreira; Antonio Di Meglio; Vianney Poinsignon; Aurelie Bardet; Gwenn Menvielle; Agnes Dumas; Sandrine Pinto; Sarah Dauchy; Leonor Fasse; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Christelle Jouannaud; Christelle Levy; Sibille Everhard; Patrick Arveux; Anne Laure Martin; Alexandra Dima; Nancy U Lin; Ann H Partridge; Suzette Delaloge; Stefan Michiels; Fabrice André; Ines Vaz-Luis
Journal:  J Clin Oncol       Date:  2020-06-22       Impact factor: 44.544

7.  Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.

Authors:  Lisette Binkhorst; Marjolein Bannink; Peter de Bruijn; Jan Ruit; Helga Droogendijk; Robbert J van Alphen; Tilly D den Boer; Mei Ho Lam; Agnes Jager; Teun van Gelder; Ron H J Mathijssen
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 8.  The Underrated Risks of Tamoxifen Drug Interactions.

Authors:  Philip D Hansten
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

9.  Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.

Authors:  Lena Klopp-Schulze; Anna Mueller-Schoell; Patrick Neven; Stijn L W Koolen; Ron H J Mathijssen; Markus Joerger; Charlotte Kloft
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810

10.  Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.

Authors:  Stefan A J Buck; C Louwrens Braal; Maaike M Hofman; Esther Oomen-de Hoop; Peter de Bruijn; Inge M Ghobadi Moghaddam-Helmantel; Koen G A M Hussaarts; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Ron H N van Schaik; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen
Journal:  Ther Adv Med Oncol       Date:  2022-03-17       Impact factor: 8.168
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.